1154757-24-0

Plazomicin (PLZ) is a novel aminoglycoside approved by the U.S. Food and Drug Administration (FDA) for the treatment of complicated urinary tract infections (cUTI, including acute pyelonephritis) in adults due to multidrug-resistant carbapenem-resistant Enterobacterales (CRE) or extended-spectrum beta-lactamase (ESBL) producing bacteria. Despite the FDA Black Box Warning for aminoglycoside class effects, PLZ exhibited a favourable safety profile with decreased adverse effects in the largest in-human trials. In vitro, activity of PLZ, in comparison with that of other aminoglycosides, was found to be excellent, with 92.3% to 98.0% overall susceptibility in Enterobacterales, including CRE. Recently, PLZ was also shown to be active against certain multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative pathogens for which limited treatment options are left[1-2].

Plazomicin is a neoglycoside antibiotic with activity against a broad range of Gram-positive and Gram-negive pathogens. Plazomicin showed potent in vitro activity against multidrug-resistant Klebsiella pneumoniae and Escherichia coli.

Plazomicin is a neoglycoside antibiotic with activity against a broad range of Gram-positive and Gram-negive pathogens. Plazomicin showed potent in vitro activity against multidrug-resistant Klebsiella pneumoniae and Escherichia coli.

[1] Kristy M Shaeer. “Plazomicin: A Next-Generation Aminoglycoside.” Pharmacotherapy 39 1 (2019): 77–93.
[2] Laurine S Blanchard. “Multicenter Clinical Evaluation of ETEST Plazomicin (PLZ) for Susceptibility Testing of Enterobacterales.” Journal of Clinical Microbiology 60 1 (2022): e0183121.